Supernus Pharmaceuticals, Inc. (SUPN)
USD 35.46
(-2.1%)
USD 35.46
(-2.1%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 77.4 Million USD | -15.44% |
| 2022 | 91.54 Million USD | 6.49% |
| 2021 | 85.95 Million USD | 77.88% |
| 2020 | 48.32 Million USD | 81.48% |
| 2019 | 26.62 Million USD | 3.78% |
| 2018 | 25.65 Million USD | 57.38% |
| 2017 | 16.3 Million USD | -2.96% |
| 2016 | 16.8 Million USD | 33.48% |
| 2015 | 12.58 Million USD | -6.35% |
| 2014 | 13.44 Million USD | 87.93% |
| 2013 | 7.15 Million USD | 520.83% |
| 2012 | 1.15 Million USD | 196.14% |
| 2011 | 389 Thousand USD | -94.24% |
| 2010 | 6.75 Million USD | 187.81% |
| 2009 | 2.34 Million USD | -64.16% |
| 2008 | 6.54 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 75.07 Million USD | -3.01% |
| 2024 Q3 | 63.98 Million USD | -6.12% |
| 2024 Q2 | 68.15 Million USD | -9.22% |
| 2023 FY | 77.4 Million USD | -15.44% |
| 2023 Q1 | 91.14 Million USD | -0.43% |
| 2023 Q3 | 83.48 Million USD | -7.82% |
| 2023 Q2 | 90.56 Million USD | -0.64% |
| 2023 Q4 | 77.4 Million USD | -7.27% |
| 2022 Q3 | 83.16 Million USD | -2.0% |
| 2022 FY | 91.54 Million USD | 6.49% |
| 2022 Q1 | 88.79 Million USD | 3.3% |
| 2022 Q2 | 84.86 Million USD | -4.43% |
| 2022 Q4 | 91.54 Million USD | 10.07% |
| 2021 FY | 85.95 Million USD | 77.88% |
| 2021 Q3 | 60.15 Million USD | 3.02% |
| 2021 Q2 | 58.39 Million USD | 16.26% |
| 2021 Q1 | 50.22 Million USD | 3.93% |
| 2021 Q4 | 85.95 Million USD | 42.9% |
| 2020 Q3 | 42.46 Million USD | 20.17% |
| 2020 FY | 48.32 Million USD | 81.48% |
| 2020 Q1 | 24.41 Million USD | -8.3% |
| 2020 Q2 | 35.33 Million USD | 44.72% |
| 2020 Q4 | 48.32 Million USD | 13.8% |
| 2019 Q2 | 26.02 Million USD | -1.86% |
| 2019 Q1 | 26.51 Million USD | 3.35% |
| 2019 Q3 | 25.5 Million USD | -2.0% |
| 2019 FY | 26.62 Million USD | 3.78% |
| 2019 Q4 | 26.62 Million USD | 4.41% |
| 2018 Q4 | 25.65 Million USD | 10.22% |
| 2018 Q3 | 23.28 Million USD | 12.57% |
| 2018 FY | 25.65 Million USD | 57.38% |
| 2018 Q2 | 20.68 Million USD | 8.41% |
| 2018 Q1 | 19.07 Million USD | 17.0% |
| 2017 Q4 | 16.3 Million USD | 9.08% |
| 2017 Q3 | 14.94 Million USD | -10.08% |
| 2017 Q2 | 16.62 Million USD | -13.27% |
| 2017 Q1 | 19.16 Million USD | 14.08% |
| 2017 FY | 16.3 Million USD | -2.96% |
| 2016 FY | 16.8 Million USD | 33.48% |
| 2016 Q1 | 13.04 Million USD | 3.63% |
| 2016 Q3 | 17.45 Million USD | 6.6% |
| 2016 Q4 | 16.8 Million USD | -3.74% |
| 2016 Q2 | 16.37 Million USD | 25.52% |
| 2015 Q1 | 13.7 Million USD | 1.94% |
| 2015 FY | 12.58 Million USD | -6.35% |
| 2015 Q4 | 12.58 Million USD | -14.62% |
| 2015 Q3 | 14.74 Million USD | 8.46% |
| 2015 Q2 | 13.59 Million USD | -0.8% |
| 2014 Q1 | 7.95 Million USD | 11.26% |
| 2014 FY | 13.44 Million USD | 87.93% |
| 2014 Q4 | 13.44 Million USD | 20.6% |
| 2014 Q3 | 11.14 Million USD | 10.34% |
| 2014 Q2 | 10.1 Million USD | 26.94% |
| 2013 Q3 | 5.18 Million USD | 20.23% |
| 2013 Q4 | 7.15 Million USD | 37.86% |
| 2013 Q1 | 3.11 Million USD | 170.23% |
| 2013 FY | 7.15 Million USD | 520.83% |
| 2013 Q2 | 4.31 Million USD | 38.61% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | 26 Thousand USD | 0.0% |
| 2012 Q4 | 1.15 Million USD | 4330.77% |
| 2012 FY | 1.15 Million USD | 196.14% |
| 2012 Q1 | - USD | -100.0% |
| 2011 FY | 389 Thousand USD | -94.24% |
| 2011 Q3 | 3.99 Million USD | 0.0% |
| 2011 Q4 | 389 Thousand USD | -90.26% |
| 2010 FY | 6.75 Million USD | 187.81% |
| 2010 Q4 | 6.75 Million USD | 246.29% |
| 2010 Q3 | 1.95 Million USD | 0.0% |
| 2009 FY | 2.34 Million USD | -64.16% |
| 2009 Q4 | 2.34 Million USD | 0.0% |
| 2008 FY | 6.54 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Theratechnologies Inc. | 6.06 Million USD | -1176.096% |
| Harrow Health, Inc. | 10.86 Million USD | -612.322% |
| Dynavax Technologies Corporation | 53.29 Million USD | -45.258% |
| Biofrontera Inc. | 10.9 Million USD | -609.644% |
| Cronos Group Inc. | 30.33 Million USD | -155.144% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | -2746.929% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -7740799900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | -1258.266% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | -1579.365% |
| Radius Health, Inc. | 278.64 Million USD | 72.22% |
| Universe Pharmaceuticals INC | 3.34 Million USD | -2215.341% |
| DURECT Corporation | 2.21 Million USD | -3388.418% |
| ProPhase Labs, Inc. | 3.84 Million USD | -1915.309% |
| Safety Shot Inc | 1.86 Million USD | -4040.247% |
| Phibro Animal Health Corporation | 265.91 Million USD | 70.89% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -9459.411% |
| Alvotech | 74.43 Million USD | -3.997% |
| Assertio Holdings, Inc. | 37.68 Million USD | -105.403% |
| Rockwell Medical, Inc. | 5.87 Million USD | -1218.481% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -1249.805% |
| Procaps Group S.A. | 96.83 Million USD | 20.06% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | -564.617% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| Aytu BioPharma, Inc. | 12.63 Million USD | -512.744% |
| Viatris Inc. | 3.46 Billion USD | 97.769% |
| OptiNose, Inc. | 8.05 Million USD | -861.351% |
| SIGA Technologies, Inc. | 64.21 Million USD | -20.539% |
| Tilray Brands, Inc. | 252.08 Million USD | 69.293% |
| PetIQ, Inc. | 159.3 Million USD | 51.41% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -1249.805% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -102.11% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -2791.474% |
| Alimera Sciences, Inc. | 1.87 Million USD | -4019.638% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | -139.416% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 28.25 Million USD | -173.982% |
| Journey Medical Corporation | 10.2 Million USD | -658.456% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -4706.783% |
| Alpha Teknova, Inc. | 11.59 Million USD | -567.656% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | -1626.701% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | -93.622% |
| PainReform Ltd. | - USD | -Infinity% |
| Cosmos Health Inc. | 4.78 Million USD | -1516.353% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | -645.742% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Embecta Corp. | 152.1 Million USD | 49.107% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 50766.981% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 25.821% |
| Incannex Healthcare Limited | -10.01 Million USD | 872.921% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -30333.415% |
| Shineco, Inc. | 1.58 Million USD | -4772.948% |
| Procaps Group, S.A. | 96.83 Million USD | 20.06% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 30.386% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | -1043.566% |
| Lantheus Holdings, Inc. | 64.02 Million USD | -20.895% |
| Alvotech | 74.43 Million USD | -3.997% |
| Hempacco Co., Inc. | 2.54 Million USD | -2944.409% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | -61.962% |
| Bright Green Corporation | - USD | -Infinity% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -17.959% |
| Kamada Ltd. | 87.74 Million USD | 11.782% |
| Indivior PLC | 141.79 Million USD | 45.41% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -15965.084% |
| Flora Growth Corp. | 8.5 Million USD | -809.826% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -30333.415% |
| Evolus, Inc. | 10.99 Million USD | -603.837% |
| HUTCHMED (China) Limited | 50.25 Million USD | -54.021% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 26.858% |
| Akanda Corp. | 1.28 Million USD | -5915.103% |